Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li><a href="https://markets.businessinsider.com/stocks/arct-stock">Arcturus Therapeutics</a> fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates. </li><li>Analysts from Barclays, Raymond James, and Baird all downgraded their ratings for <keyword id="250021" type="CITY" weightage="60" keywordseo="Arcturus">Arcturus</keyword> on Tuesday. </li><li>Arcturus released clinical and preclinical data for its COVID-19 vaccine candidate, ARCT-021, on Monday while also announcing that the Singapore Health Sciences Authority approved the vaccine for Phase 2 clinical studies. </li><li>Barclays analyst Gena Wang wrote that the interim data of the vaccine candidate was "disappointing," <a href="https://seekingalpha.com/news/3647704-arcturus-gets-multiple-downgrades-after-updating-covidminus-19-vaccine-trial-data">per</a> Seeking Alpha. </li><li><a href="https://markets.businessinsider.com/stocks/arct-stock">Watch Arcturus Therapeutics trade live here.</a></li></ul><a href="https://markets.businessinsider.com/stocks/arct-stock">Arcturus Therapeutics</a> fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates. Arcturus <a href="https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-received-approval-singapore-health">released clinical and preclinical data</a> for its COVID-19 vaccine candidate, ARCT-021 on Monday while also announcing that the Singapore Health Sciences Authority approved the vaccine for Phase 2 clinical studies. Barclays called the interim data of the vaccine candidate "disappointing," according to a report <a href="https://seekingalpha.com/news/3647704-arcturus-gets-multiple-downgrades-after-updating-covidminus-19-vaccine-trial-data">cited by Seeking Alpha</a>. Analyst Gena Wang wrote that higher dose animal studies showed some efficacy, but "safety concerns limited further dose escalation."The firm downgraded its rating for Arcturus from "overweight" to "equal weight." Barclays holds a price target of $46 for the stock. Raymond James also downgraded its rating from "outperform"to "market perform," while Baird analysts downgraded the stock from "outperform" to "neutral" and lowered its price target from $79 to $69. Read more:<a href="https://www.businessinsider.com/investing-strategy-fund-manager-trend-following-nasdaq-futures-jason-teed-2020-12">Jason Teed has beaten 99% of his investor peers this year. He breaks down how his Morningstar gold-rated fund did it with a trend-following strategy, and shares his advice for navigating the stock market in 2021.</a>Shares of Arcturus currently trade around $42.Meanwhile, Piper Sandler senior biotech analyst Yasmeen Rahimi said she was disappointed in the vaccine candidate's neutralizing titers, but "compelled by the robust pre-clinical data supporting T-cell-driven efficacy, and continue[s] to believe in ARCT's mRNA technology." Rahimi rates Arcturus "overweight" and has a price target of $140 for the stock.Last week, Arcturus boasted a 989% year-to-date gain. Monday and Tuesday's sell-off has erased those gains, but the stock has still returned over 290% this year. According to <a href="https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-received-approval-singapore-health">Arcturus</a>, no safety concerns were identified with the vaccine candidate and all adverse events except 2 were mild or moderate at doses selected for Phase 2.

Arcturus Therapeutics plummets 53% after analyst downgrades following COVID-19 vaccine trial updates

<ul class="summary-list"><li>Viral infections, including COVID, can cause pink eye.</li><li>Experts are worried that the new "Arcturus" variant may be causing more of the eye irritation.</li></ul>If you're experiencing red, irritated eyes this spring, it may not be seasonal allergies — it could be a sign you have COVID.Doctors and patients alike are experiencing more cases of viral pink eye during COVID infections, as new variants including one <a href="https://theconversation.com/arcturus-what-to-know-about-the-new-covid-variant-omicron-xbb-1-16-204598" target="_blank" rel="noopener">called "Arcturus,"</a> or XBB.1.16, spread across the US. "Observational data suggests that people infected with XBB.1.16 may be more likely to experience conjunctivitis as a symptom of their COVID infection," the <a href="http://ph.lacounty.gov/phcommon/public/media/mediapubhpdetail.cfm?prid=4372" target="_blank" rel="noopener">Los Angeles health department</a> said in a release. "Be aware that itchy, watery or red eyes may be a sign of a COVID-19 infection."On Tiktok, one man said the eye irritation he had after a week of severe cold symptoms got so bad that "my eye was pretty much swollen shut for a few days." "I had to take multiple trips to the opthamologist and even the ER at one point," he said, because white, floppy "pseudomembranes" were growing in his eyes, "covering the inside of my eyelids and over my eyes." Opthamologist Vicki Chan said in a TikTok video that pseudomembranes are essentially "white cells and pus and fibrin which has congealed on the eye." They can be usually be <a href="https://casereports.bmj.com/content/12/3/e228538#ref-1:~:text=easily%20peeled%20off%20leaving%20an%20intact%20underlying%20epithelium" target="_blank" rel="noopener">peeled off or pulled out of the eye</a>, and eye doctors may prescribe steroid drops to keep them from coming back afterwards. It's not unusual for people with viral infections to get pink eye, which is <a href="https://www.cdc.gov/conjunctivitis/about/causes.html" target="_blank" rel="noopener">usually caused by a virus</a> or bacteria. Previous studies have suggested <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264785/#:~:text=The%20overall%20rate%20of%20conjunctivitis%20was%201.1%25" target="_blank" rel="noopener">people with COVID get pink eye about 1%</a> of the time, but that rate could be increasing with the Arcturus variant.Dr. Jessica Kiss said that people might brush off viral pink eye thinking it's just their spring allergies, but she encourages everyone with eye irritation to <a href="https://www.tiktok.com/@askdrmom/video/7222683153402580266?lang=en" target="_blank" rel="noopener">test for COVID</a>. "I think this was the first symptom I had the last time I had COVID," she said on TikTok.

A man discovered a pus-filled 'pseudomembrane' in his eye after getting a COVID-induced pink eye infection

The <keyword id="13772791" type="General" weightage="20" keywordseo="New-Omicron-subvariant" source="Orion">new Omicron subvariant</keyword> XBB.1.16 is spreading fast in the US, becoming the second dominant Covid-19 strain in the country, according to the latest data by the Centers for Disease Control and Prevention (CDC). The subvariant, referred to as "arcturus", has accounted for about 12 per cent of new weekly Covid-19 cases reported in the country, up from 7.4 per cent the week prior, Xinhua news agency quoted the CDC data published on Friday as saying. Experts warned the percentage is expected to increase in the coming weeks, possibly become the next dominant coronavirus strain in the country. The highly transmissible Omicron subvariant XBB.1.5 remains the dominant strain in the US and accounted for about 68.8 per cent of new Covid-19 cases this week, the CDC data revealed. The <keyword id="43588" type="General" weightage="20" keywordseo="World-Health-Organization" source="Orion">World Health Organization</keyword> is monitoring XBB.1.16, which is contributing to the ongoing resurgence of Covid-19 in India. The US continues to remain the worst hit country in the world with the highest number of Covid-19 cases and deaths. As of Saturday morning, the country's overall caseload and death toll stood at 106,627,427 and 1,159,824, respectively. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/ultratech-cements-q4-net-profit-falls-32-to-1666-crore-declares-dividend/articleshow/99848912.cms">UltraTech Cement’s Q4 net profit falls 32% to ₹1,666 crore, declares dividend</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/careers/news/these-qualifications-will-help-you-snag-the-best-tech-jobs/slidelist/99838842.cms">These qualifications will help you snag the best paying tech jobs in BFSI sector</a>

New Omicron subvariant becomes 2nd dominant strain in US

<ul class="summary-list"><li>Etsy is full of accounts selling alien products that promise intergalactic healing technology.</li><li>Some promote the conspiracy theory that 5G is harmful, claiming alien products can be protective.</li></ul>For just over $50, you can buy a 30 minute Skype session on Etsy that promises access to the healing technology of the Arcturians, an alien species from the planet Arcturus.The seller named Venus, who owns the Etsy store TheMysticalElven, says in the description she started her own journey as an intuitive energy healer when she was "astrally taken aboard starships and healed from birth issues." Thanks to the healing powers of the Arcturians, she writes, she has been able to see her own past lives, and has permission from her "star family" to invite others into the experience. The price "is decided entirely by them," she states.Whoever buys one of these sessions will be connected with their star family, she says, and will visit one of six star ships that are currently in Earth's orbit through astral projection.Venus' astral projection is just one of many packages available on Etsy from multiple sellers promising healing benefits through similar Arcturus connections. Etsy is also full of sellers claiming they have products inspired by Arcturus technology that can protect against electromagnetic fields and 5G waves — common fears among conspiracy theorists that have no scientific basis. This intergalactic genre is a slice of the countless products being sold that promise to ward off the imaginary negative effects of 5G — some of the more extensive sculptures that tout their cleansing powers are being sold for over $5,000.Insider reviewed dozens of products and accounts on Etsy that claim to offer health benefits or claim to promote wealth, fertility, and other advantages. These products appear to violate Etsy's own policies on prohibited services, which state that "metaphysical services" such as distance healing, rituals and items that promise "attracting wealth" or "love" are not allowed on the marketplace. A representative for Etsy declined to comment on whether these products are in violation of the store's terms of service.<h2>Intergalactic healing, now 20% off</h2>Venus' healing sessions, talismans, and spells have been purchased 4,920 times, and she has an average rating of five stars on her store. "I was taken on the Arcturian mothership for healing," one review reads, stating they were able to connect to "the highest of realms" through Venus' teaching. Others thank her for healing their allergies and physical injuries.Venus adds a disclaimer that to remain in line with Etsy's policies, she has to state that her sessions are sold "for entertainment purposes only." (Venus did not return Insider's request for comment.)Other sellers have products that feature similar services also have hundreds of reviews under their products, such as Erika who runs the store called TwinFlameStarseed, who says her video reading "helps you to raise your vibration" which prepares the buyer for the alien "healing chambers," through "highly advanced quantum technology." In a long email to Insider, she said she personally uses Arcturian medbeds, and helps her clients access their "galactic record." Shops run by accounts named IntGalacticPriestess and StarseedsUnited have sold hundreds of their readings that will identify whether or not a customer has alien ancestry or not.Although there is nothing wrong with believing in extraordinary things in theory, misinformation experts say there's the potential for these beliefs to overlap with extremist conspiracy theories, such as belief in QAnon and anti-vaccine falsehoods. Sara Aniano, a disinformation analyst at ADL Center on Extremism told Insider these concepts rarely exist in a vacuum. Believing that 5G is harmful, for instance, is almost always "in conjunction with pushing back against modern medicine," she said."I haven't seen a case where they don't espouse other conspiratorial beliefs, whether that is related to health and wellness, or related to election fraud, or anti-government conspiritism, or anti-vax stuff," she said. "It's all quite well connected."With these beliefs at an all time high due to political instability and fears surrounding the coronavirus pandemic, opportunists are poised to make a significant amount of money.<div type="image" title="Etsy medbed alien" height="460" width="999" msid="93528369" hostid="261" sizebytes="53834"></div>Alien "orgonite" products that are popular on Etsy, for instance, are available for around $30 each. They are based on the pseudoscientific belief popularized in the 1940s by psychoanalyst and doctor Wilhelm Reich, which states there is a universal life force of "orgone" energy which can be collected and then used to treat physical and mental ailments. The orgonite ornaments on Etsy — blueish purple in color, and shaped like mandalas, alien heads, and pyramids — are described as being inspired by the teachings of the Arcturians. These aliens are "loving and compassionate," and "work for our highest potential for our highest good," one description reads.This seller describes a towerbuster — a device used to supposedly collect orgone — as being "encoded and activated" with "galactic healing frequencies" and "quantum healing techniques" which "help cleanse your aura and your space.""These pieces transmute negative energy by moving it through a dense matrix of minerals combined to create high piezoelectric activity and energetic transmutation," it says.<h2>Conspiracy theories are extremely profitable</h2>Samantha North, a PhD researcher at the University of Bath who <a href="https://samanthanorth.com/">specializes in disinformation</a>, told Insider people are attracted to these kinds of products for a few different reasons. One is that they can use them as a "badge of honor" to show allegiance with those who are also "enlightened," and to mark them out from the ordinary "sheeple," she said."If they're true believers, then they really do feel safer having bought these products," she added. "They're likely to share them with their loved ones because they want them to be safe too."Aniano said an individual has the right to believe in whatever they want to, but it's when other people get coerced into the same thing that issues can arise. She pointed to the case of one woman in Texas who got so concerned that 5G waves were harming her daughter, she lived in a van for a while trying to escape them.Aniano also sees these kinds of beliefs as rife for people to financially benefit from if they wish to."Conspiracy theories are fascinating and they give people a lot of hope where hope may not really exist," she said. "And all of those things make these topics extremely profitable."

Etsy is full of accounts selling alien products that promise intergalactic healing and protection from 5G

<ul><li>US <keyword id="6354298" type="DEFINITION" weightage="60" keywordseo="Stocks">stocks</keyword> on Tuesday pulled back from record highs as hopes for $2,000 direct <keyword id="45304" type="COMPANY" weightage="60" keywordseo="Stimulus">stimulus</keyword> payments faded. </li><li>Senate Majority Leader Mitch McConnell on Tuesday <a href="https://www.businessinsider.com/mcconnell-senate-2000-stimulus-checks-2020-12">blocked Democrats' attempt</a> to hold a vote on the $2,000 checks, but he said the Senate would "begin a process" of considering a proposal to send them.</li><li><a href="https://markets.businessinsider.com/news/stocks/intel-stock-price-third-point-urges-chipmaker-explore-strategic-alternatives-2020-12-1029924016">Intel soared 8%</a> after Daniel Loeb's activist hedge fund urged the chipmaker in a letter to explore strategic alternatives, Reuters reported.</li><li>Goldman Sachs said Snap Inc. <a href="https://markets.businessinsider.com/news/stocks/snapchat-stock-price-product-driven-revenue-growth-goldman-says-2020-12-1029923585">could surge 45%</a> as its product developments drive faster-than-expected revenue growth. </li><li><a href="https://markets.businessinsider.com/indices">Watch major indexes update live here</a>.</li></ul>US stocks on Tuesday pulled back from record highs as hopes for $2,000 direct stimulus payments faded.Senate Majority Leader Mitch McConnell <a href="https://www.businessinsider.com/mcconnell-senate-2000-stimulus-checks-2020-12">blocked an attempt by Democrats</a> to hold a vote on the $2,000 checks but said the Senate would "begin a process" of considering a proposal to send them to Americans - a measure that Democrats and President Donald Trump have pushed for.Senate Minority Leader Chuck Schumer had called for a vote in the Senate on Tuesday after the House passed supplemental legislation known as the CASH Act on Monday night.Here's where US indexes stood after the 4 p.m. ET close on Tuesday:<ul><li><a href="https://markets.businessinsider.com/index/s&amp;p_500_500" target="_blank" rel="noopener">S&amp;P 500</a>: 3,727.04, down 0.22%</li><li><a href="https://markets.businessinsider.com/index/dow_jones" target="_blank" rel="noopener">Dow Jones industrial average</a>: 30,335.67, down 0.22% (68.30 points)</li><li><a href="https://markets.businessinsider.com/index/nasdaq_composite" target="_blank" rel="noopener">Nasdaq composite</a>: 12,850.22, down 0.38%</li></ul>Read more: <a href="https://www.businessinsider.com/how-small-investors-making-passive-income-in-rental-real-estate-2020-12">Small investors with no background in finance or real estate are making up to $29,000 a month in run-down properties. Here are 4 tips for those looking to do the same.</a><a href="https://markets.businessinsider.com/news/stocks/intel-stock-price-third-point-urges-chipmaker-explore-strategic-alternatives-2020-12-1029924016">Intel soared 8%</a> after Daniel Loeb's activist hedge fund, Third Point, sent a letter to the chipmaker urging it to explore strategic alternatives, <a href="https://www.reuters.com/article/us-intel-thirdpoint-exclusive/exclusive-hedge-fund-third-point-urges-intel-to-explore-deal-options-idUKKBN2931PS">according to Reuters</a>."Without immediate change at Intel, we fear that America's access to leading-edge semiconductor supply will erode, forcing the US to rely more heavily on a geopolitically unstable East Asia to power everything from PCs to data centers to critical infrastructure," the letter said.Goldman Sachs said Snap Inc., Snapchat's parent company, <a href="https://markets.businessinsider.com/news/stocks/snapchat-stock-price-product-driven-revenue-growth-goldman-says-2020-12-1029923585">could surge 45%</a> as its product developments drive faster-than-expected revenue growth. The firm reiterated its "buy" rating on the stock and set a $70 price target for the company, which helped to propel an 11% jump for Snap on Tuesday.<a href="https://markets.businessinsider.com/news/stocks/arcturus-therapeutics-stock-price-analyst-downgrades-covid19-vaccine-trail-updates-singapore-2020-12-1029923922">Arcturus Therapeutics fell as much as 53%</a>, to $40, extending its losses for the second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates. Analysts from Barclays, Raymond James, and Baird all downgraded their ratings for Arcturus on Tuesday.Oil prices were up. <a href="https://markets.businessinsider.com/commodities/oil-price?type=wti">West Texas Intermediate crude</a> increased 0.76%, to $47.89 per barrel. <a href="https://markets.businessinsider.com/commodities/oil-price?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingestts&amp;utm_medium=ingest">Brent crude</a>, oil's international benchmark, increased 0.35% to $51.04 per barrel.<a href="https://markets.businessinsider.com/commodities/gold-price">Gold</a> increased 0.65%, to $1,883.50 per ounce.Read more: <a href="https://www.businessinsider.com/investing-strategy-fund-manager-trend-following-nasdaq-futures-jason-teed-2020-12">Jason Teed has beaten 99% of his investor peers this year. He breaks down how his Morningstar gold-rated fund did it with a trend-following strategy, and shares his advice for navigating the stock market in 2021.</a>

US stocks slide from new highs as hope for expanded stimulus fades

REUTERS/Andreas GebertEmployee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen, Germany, March 12, 2020. Picture taken on March 12, 2020. REUTERS/Andreas Gebert<ul class="summary-list"><li>To respond to the <a href="https://www.businessinsider.com/china-virus-everything-we-know-deadly-2019-ncov-wuhan-spread-2020-1">coronavirus pandemic</a>, drug companies have begun researching <a href="https://www.businessinsider.com/wuhan-coronavirus-treatments-vaccine-jj-regeneron-gilead-2020-2">potential treatments and vaccines</a>.</li><li>One of those vaccine developers, a privately held Germany biotech company called CureVac, hopes to begin testing a potential vaccine in people in June.</li><li>A German newspaper <a href="https://www.welt.de/wirtschaft/plus206563595/Trump-will-deutsche-Impfstoff-Firma-CureVac-Traumatische-Erfahrung.html">reported Sunday</a> that Trump administration officials offered large sums of cash to CureVac to secure for the rights the vaccine, "but only for the USA." The company <a href="https://twitter.com/CureVacAG/status/1239535638359281664">denied Monday</a> that it has received any offers from the US government.</li><li>CureVac is using a genetic technology that enables much quicker development of vaccines. Called messenger RNA (mRNA), a vaccine includes only the genetic instructions to produce a protein to fight the virus.</li><li>Despite its speed, the mRNA platform remains unproven. There are no approved vaccines based on the technology. Other biotechs developing mRNA coronavirus vaccines include Moderna, BioNTech, and Arcturus Therapeutics.</li><li><a href="https://www.businessinsider.com/?hprecirc-bullet">Visit Business Insider's homepage for more stories</a>.</li></ul>The sprint to develop a <a href="https://www.businessinsider.com/coronavirus-vaccine-timeline-what-to-watch-leading-research-2020-3">coronavirus vaccine</a> is on in full force.While <a href="https://www.businessinsider.com/wuhan-coronavirus-treatments-vaccine-jj-regeneron-gilead-2020-2">dozens of research programs</a> are underway, many of the vaccine developers that have put out the fastest timelines for bringing a vaccine into the clinic for human testing share a similarity: the technology they're relying on.These drug companies are looking to develop a vaccine using messenger RNA (mRNA) platform technology - a novel method that has yet to produce an approved vaccine, but holds tremendous promise.The first potential coronavirus vaccine was <a href="https://www.businessinsider.com/coronavirus-vaccine-first-dose-administered-in-clinical-trial-2020-3">injected into clinical trial participants</a> on Monday. That experimental vaccine was made by Moderna, a Massachusetts-based biotech upstart that uses an mRNA platform. BioNTech, a $9 billion German drugmaker, also <a href="https://investors.biontech.de/news-releases/news-release-details/biontech-reports-rapid-progress-covid-19-vaccine-program-address">said Monday</a> it plans to start clinical testing of its mRNA vaccine in late April. <h2>Reports of an offer, and a denial</h2>The privately held German biotech company CureVac is also researching an mRNA vaccine. The company gained widespread attention over the weekend after <a href="https://www.welt.de/wirtschaft/plus206563595/Trump-will-deutsche-Impfstoff-Firma-CureVac-Traumatische-Erfahrung.html">the German newspaper Welt am Sonntag reported</a> that a Trump administration officials offered large sums of money for rights to its vaccine, "but only for the USA." CureVac <a href="https://twitter.com/CureVacAG/status/1239535638359281664">denied on Monday</a> that it has received any such offers from the US government. Just a few days before those reports, CureVac switched CEOs on March 11, re-installing its longtime leader and founder Ingmar Hoerr. Previous CEO Daniel Menichella <a href="https://www.curevac.com/news/company-founder-ingmar-hoerr-succeeds-daniel-menichella-as-ceo-of-curevac-ag">left the company</a>, effective immediately. On Monday, Hoerr <a href="https://www.curevac.com/news/curevac-announces-leadership-update">took a leave of absence for medical reasons</a>, and Deputy CEO Franz-Werner Haas was put in control of the company.Hoerr cofounded CureVac in 2000 and served as CEO until 2018, when Menichella took over. While Hoerr is based in Germany, Menichella worked out of Boston. The company has about 500 employees and offices in Boston, Frankfurt, and Tübingen, Germany.<h2>'We have to get focused'</h2>Menichella also a March 2 roundtable of pharmaceutical-industry leaders at the White House, where he discussed CureVac's vaccine research with President Donald Trump and Vice President Mike Pence, among others. On March 12, the day after news was released of the CEO switch, Hoerr spoke with Business Insider about CureVac's research and the recent change in leadership. The conversation took place before press reports about a reported offer from US officials for its vaccine work.In that interview, Hoerr told Business Insider the CEO change had more to do with the company's focus on research, rather than on business development. In particular, Hoerr cited his own research expertise (the company was founded in part around his Ph.D. work) as a key driver in working on a coronavirus vaccine. "I think every phase has a CEO fitting for the company," Hoerr said. "[Menichella] had a good fit the last two years, and now I might have a good fit now to get these things done and get to the market." Hoerr said Menichella was focused more on business negotiations, "but now we really have to get focused on the corona thing and get things done." <h2>CureVac's vaccine could be tested in people in June or July</h2>Menichella previously provided an ambitious timeline for CureVac's work. During the White House meeting, he said the company planned to start a clinical trial by the beginning of June. Hoerr said he expects to start a clinical study in either June or July for the coronavirus vaccine.He also stressed that CureVac has the ability to mass produce a vaccine if needed in a time of emergency. He outlined how an early safety study, called a Phase 1 trial, could expand to a large population in the case of an emergency: "If there's an emergency in Germany, and you start with maybe 10 volunteers for the Phase 1 ,then they extend to 100 then they might extend to thousands, especially in at-risk areas," he said"They can still run this clinical trial and extend as long as they want. They can do 10,000, they can get to 100,000, they can get to 1 million if they want to. It's all there. We all have the material ready to do so. It's quite encouraging to see that we can really do something against corona because we have this material ready," he said.Hoerr added the company currently has the manufacturing capability to deliver 10 million doses of a 1-microgram vaccine.<ul class="read-more-links"><li>Read more:</li><li><a href="https://www.businessinsider.com/trump-administration-tried-to-pay-germans-scientists-for-coronavirus-cure-2020-3">Trump reportedly tried to poach German scientists working on a coronavirus vaccine and offered cash so it would be exclusive to the US</a></li><li><a href="https://www.businessinsider.com/coronavirus-vaccine-timeline-what-to-watch-leading-research-2020-3">There are at least 35 potential coronavirus vaccines in the works, aiming to halt the pandemic. Here are the top efforts to watch and what to expect in 2020 and beyond.</a></li><li><a href="https://www.businessinsider.com/wuhan-coronavirus-treatments-vaccine-jj-regeneron-gilead-2020-2">The US is sprinting to develop a coronavirus vaccine or treatment. Here's how 10 top drugmakers are racing to tackle the pandemic.</a></li></ul><a href="/intelligence/digital-health?IR=T&amp;itm_source=businessinsider&amp;itm_medium=ctgr_bii&amp;itm_term=ctgr_subscription&amp;itm_content=health&amp;itm_campaign=digital-health"></a>Featured Digital Health Articles: - <a href="/telehealth-industry-explained">Telehealth Industry: Benefits, Services &amp; Examples</a> - <a href="/value-based-care-pay-for-performance-healthcare-model">Value-Based Care Model: Pay-for-Performance Healthcare</a> - <a href="/senior-care-market-trends">Senior Care &amp; Assisted Living Market Trends</a> - <a href="/wearable-technology-healthcare-medical-devices">Smart Medical Devices: Wearable Tech in Healthcare</a> - <a href="/artificial-intelligence-healthcare">AI in Healthcare</a> - <a href="/remote-patient-monitoring-industry-explained">Remote Patient Monitoring Industry: Devices &amp; Market Trends</a>

You Searched For "Arcturus" and got 6 results

Arcturus Therapeutics plummets 53% after analyst downgrades following COVID-19 vaccine trial updates

Emily Graffeo

A man discovered a pus-filled 'pseudomembrane' in his eye after getting a COVID-induced pink eye infection

Hilary Brueck

New Omicron subvariant becomes 2nd dominant strain in US

IANS

Etsy is full of accounts selling alien products that promise intergalactic healing and protection from 5G

Lindsay Dodgson

US stocks slide from new highs as hope for expanded stimulus fades

Emily Graffeo

Everything you need to know about CureVac, the German drugmaker working on a coronavirus vaccine that's at the heart of a US-German controversy

Zachary Tracer

Popular Keywords

Buying Guides